Abstract
Research revealed that in vitro activity ofchloroquine and the derivative
molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and
SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and
chloroquine phosphate for the critical patients of COVID-19. The clinical trials
supported that the hydroxychloroquine did not substantially reduce the system severity
in non-hospitalized persons. Moreover, it also produces severe side effects like
drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.
Keywords: Controlled randomized trial, COVID-19, Hydroxy chloroquine (HCQ), Post exposure prophylaxis, SARS-CoV-2, Therapy.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Aging Science
Anti-Infective Agents
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents